Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Morse

, Califf

, Sugarman

. Monitoring and ensuring safety during clinical research. JAMA 2001;285:1201–1205.

National Institutes of Health. NIH Policy for Data and Safety Monitoring. June 10, 1998. http://grants.nih.gov/grants/guide/notice-files/not98-084.html.

National Institutes of Health. Recommendations to General Clinical Research Centers (GCRCs) for Patient Safety in Clinical Research. May 17, 2001. http://www.ncrr.nih.gov/clinical/gcrcpatientsafety20010622.html.

National Institutes of Health. Recommendations to GCRCs for Patient Safety in Clinical Research. http://www.ncrr.nih.gov/clinical.html.

NCRR creates new GCRC research subject ombudsman position. J Investig Med 2001;49222.

Pocock

, Furberg

CD.

Procedures of data and safety monitoring committees. Am Heart J 2001;141:289–294.

Wittes

Behind closed doors: The data monitoring board in randomized clinical trials. Stat Med 1993;12:419–424.

Califf

, Ellenberg

SS.

Statistical approaches and policies for the operations of Data and Safety Monitoring Committees. Am Heart J 2001;141:301–305.

DeMets

, Pocock

, Julian

DG.

The agonising negative trend in monitoring of clinical trials. Lancet 1999;354:1983–1988.

10.

Bolland

, Whitehead

Formal approaches to safety monitoring of clinical trials in life-threatening conditions. Stat Med 2000;19:2899–2917.

11.

Pocock

SJ.

When to stop a clinical trial. BMJ 1992;305:235–240.

12.

Packer

, Wittes

, Stump

Terms of reference for data and safety monitoring committees. Am Heart J 2001;141:542–547.

13.

Zelen

Early stopping, interim analyses, and monitoring committees: What are the tradeoffs?

J Clin Oncol 1987;5:1314–1315.

14.

Echt

, Liebson

, Mitchell

, Peters

, Obias-Manno

, Barker

, Arensberg

, Baker

, Friedman

, Greene

, . Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781–788.

15.

Branched-chain amino acids and amyotrophic lateral sclerosis: A treatment failure?

The Italian ALS Study Group. Neurology 1993;432466–2470.

16.

McKenzie

, Fried

, Sallie

, Conjeevaram

, Di Bisceglie

, Park

, Savarese

, Kleiner

, Tsokos

, Luciano

, . Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995;333:1099–1105.

17.

Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989;321406–412.

18.

Pawitan

, Hallstrom

Statistical interim monitoring of the Cardiac Arrhythmia Suppression Trial. Stat Med 1990;9:1081–1090.

19.

Meinert

, Knatterud

, Prout

, Klimt

CR.

A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19:789–830.

20.

Prout

, Knatterud

, Meinert

, Klimt

CR.

The UGDP controversy. Clinical trials versus clinical impressions. Diabetes 1972;21:1035–1040.

21.

Friedel

, Thomas

, Fisher

RS.

Ischemic colitis during treatment with alosetron. Gastroenterology 2001;120:557–560.

22.

Friedman

, Woodcock

, Lumpkin

, Shuren

, Hass

, Thompson

LJ.

The safety of newly approved medicines: Do recent market removals mean there is a problem?

JAMA 1999;281:1728–1734.

23.

Cairns

, Hallstrom

, Held

Should all trials have a data safety and monitoring committee?

Am Heart J 2001;141:156–163.

24.

Green

, Fleming

, O'Fallon

. Policies for study monitoring and interim reporting of results. J Clin Oncol 1987;5:1477–1484.

Implementation of a Data and Safety Monitoring Program in a General Clinical Research Center

Abstract

Get full access to this article

References